# PLK1 Conjugated Antibody

Catalog No: #C32706

SAB Signalway Antibody

Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

Package Size: #C32706-AF350 100ul #C32706-AF405 100ul #C32706-AF488 100ul

#C32706-AF555 100ul #C32706-AF594 100ul #C32706-AF647 100ul

#C32706-AF680 100ul #C32706-AF750 100ul #C32706-Biotin 100ul

## Description

Product Name	PLK1 Conjugated Antibody
Host Species	Rabbit
Clonality	Polyclonal
Species Reactivity	Hu Ms Rt
Specificity	The antibody detects endogenous level of total PLK1 protein.
Immunogen Description	Recombinant protein of human PLK1.
Conjugates	Biotin AF350 AF405 AF488 AF555 AF594 AF647 AF680 AF750
Other Names	PLK;STPK13
Accession No.	Swiss-Prot#:P53350NCBI Gene ID:5347
Uniprot	P53350
GeneID	5347;
Excitation Emission	AF350: 346nm/442nm
	AF405: 401nm/421nm
	AF488: 493nm/519nm
	AF555: 555nm/565nm
	AF594: 591nm/614nm
	AF647: 651nm/667nm
	AF680: 679nm/702nm
	AF750: 749nm/775nm
Calculated MW	68
Formulation	0.01M Sodium Phosphate, 0.25M NaCl, pH 7.6, 5mg/ml Bovine Serum Albumin, 0.02% Sodium Azide
Storage	Store at 4°C in dark for 6 months

## **Application Details**

Suggested Dilution:

AF350 conjugated: most applications: 1: 50 - 1: 250
AF405 conjugated: most applications: 1: 50 - 1: 250
AF488 conjugated: most applications: 1: 50 - 1: 250
AF555 conjugated: most applications: 1: 50 - 1: 250
AF594 conjugated: most applications: 1: 50 - 1: 250
AF647 conjugated: most applications: 1: 50 - 1: 250
AF680 conjugated: most applications: 1: 50 - 1: 250
AF750 conjugated: most applications: 1: 50 - 1: 250

Biotin conjugated: working with enzyme-conjugated streptavidin, most applications: 1: 50 - 1: 1,000

### **Product Description**

Antibodies were purified by affinity purification using immunogen.

### Background

At least four distinct polo-like kinases exist in mammalian cells: PLK1, PLK2, PLK3, and PLK4/SAK (1). PLK1 apparently plays many roles during mitosis, particularly in regulating mitotic entry and exit. The mitosis promoting factor (MPF), cdc2/cyclin B1, is activated by dephosphorylation of cdc2 (Thr14/Tyr15) by cdc25C. PLK1 phosphorylates cdc25C at Ser198 and cyclin B1 at Ser133 causing translocation of these proteins from the cytoplasm to the nucleus (2-5). PLK1 phosphorylation of Myt1 at Ser426 and Thr495 has been proposed to inactivate Myt1, one of the kinases known to phosphorylate cdc2 at Thr14/Tyr15 (6). Polo-like kinases also phosphorylate the cohesin subunit SCC1, causing cohesin displacement from chromosome arms that allow for proper cohesin localization to centromeres (7). Mitotic exit requires activation of the anaphase promoting complex (APC) (8), a ubiquitin ligase responsible for removal of cohesin at centromeres, and degradation of securin, cyclin A, cyclin B1, Aurora A, and cdc20 (9). PLK1 phosphorylation of the APC subunits Apc1, cdc16, and cdc27 has been demonstrated in vitro and has been proposed as a mechanism by which mitotic exit is regulated (10,11). Substitution of Thr210 with Asp has been reported to elevate PLK1 kinase activity and delay/arrest cells in mitosis, while a Ser137Asp substitution leads to S-phase arrest (12). In addition, while DNA damage has been found to inhibit PLK1 kinase activity, the Thr210Asp mutant is resistant to this inhibition (13). PLK1 has been reported to be phosphorylated in vivo at Ser137 and Thr210 in mitosis; DNA damage prevents phosphorylation at these sites (14).

Note: This product is for in vitro research use only